Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - LogicBio Therapeutics, Inc. | d528918dex211.htm |
| EX-10.8 - EX-10.8 - LogicBio Therapeutics, Inc. | d528918dex108.htm |
| EX-10.4 - EX-10.4 - LogicBio Therapeutics, Inc. | d528918dex104.htm |
| EX-10.2 - EX-10.2 - LogicBio Therapeutics, Inc. | d528918dex102.htm |
| EX-10.1 - EX-10.1 - LogicBio Therapeutics, Inc. | d528918dex101.htm |
| EX-4.2 - EX-4.2 - LogicBio Therapeutics, Inc. | d528918dex42.htm |
| EX-3.5 - EX-3.5 - LogicBio Therapeutics, Inc. | d528918dex35.htm |
| EX-3.2 - EX-3.2 - LogicBio Therapeutics, Inc. | d528918dex32.htm |
| S-1 - S-1 - LogicBio Therapeutics, Inc. | d528918ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of our report dated August 10, 2018 relating to the consolidated financial statements of LogicBio Therapeutics, Inc. and its subsidiary (the “Company”) (which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph referring to the Company’s ability to continue as a going concern) appearing in the Prospectus, which is part of this Registration Statement.
We also consent to the reference to us under the headings “Experts” in such Prospectus.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
September 24, 2018